Introducing Starbucks Oleato™ – a Revolutionary New Coffee Ritual
Starbucks today unveiled a transformational innovation in coffee, Oleato – a line of coffee beverages that brings together the unexpected – Starbucks arabica coffee deliciously infused with a spoonful of Partanna cold pressed, extra virgin olive oil. The result is velvety smooth, delicately sweet, and lush coffee that uplifts each cup with an extraordinary new flavor and texture. The new beverage platform which launches in Starbucks stores in Italy on Feb. 22, includes: Oleato™ Caffè Latte, Oleato™ Iced Shaken Espresso, and Oleato™ Golden Foam™ Cold Brew. The Starbucks Reserve Roastery Milan will also debut five beverages to customers on Feb. 22: Oleato™ Caffè Latte, Oleato™ Iced Cortado, Oleato™ Golden Foam™ Cold Brew, Oleato™ Deconstructed, and Oleato™ Golden Foam™ Espresso Martini. Starbucks will begin to introduce the beverages in select markets around the world, starting with Southern California in the United States this spring. Later this year, Japan, the Middle East, and the United Kingdom will launch the beverages.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230221005753/en/
Introducing Starbucks Oleato™ – a Revolutionary New Coffee Ritual (Photo: Business Wire)
“During my first trip to Milan in 1983, I was captivated by the sense of community, connection, and passion for coffee I found in the city’s espresso bars. It was that trip that inspired me to bring the ritual of handcrafted espresso to Starbucks and to America. Oleato represents the next revolution in coffee that brings together an alchemy of nature’s finest ingredients – Starbucks arabica coffee beans and Partanna cold pressed extra virgin olive oil,” said Howard Schultz, Starbucks interim chief executive officer. “Today I feel just as inspired as I did 40 years ago, Oleato has opened our eyes to fresh new possibilities and a transformational way to enjoy our daily coffee,” said Schultz.
Starbucks continuous search for inspiration revealed a family tradition that has existed in regions of Italy for generations - enjoying a spoonful of extra virgin olive oil each day as an uplifting ritual. This led Starbucks to Partanna, an Italian extra virgin olive oil brand with more than 100 years of tradition and dedication to farming and crafting premium extra virgin olive oil.
Oleato, The New Coffee Ritual
Partanna created a highly curated blend of extra virgin olive oil from the finest Mediterranean olives, including the high-quality Nocellara del Belice (also called Castelvetrano) olives from Partanna, Sicily. The blend was thoughtfully selected to pair perfectly with Starbucks coffee, which is then skillfully infused in the beverage to unlock a smooth and delicious experience like no other.
Starbucks Oleato beverages that will be served in Starbucks stores around the world:
- Oleato™ Caffè Latte : Starbucks Blonde Espresso Roast, a light roast that is smooth and subtly sweet, is infused with Partanna extra virgin olive oil and steamed with creamy oatmilk to create a velvety smooth, deliciously lush latte.
- Oleato™ Golden Foam™ Cold Brew : The inviting aroma of lush Partanna extra virgin olive oil infused cold foam cascades slowly through the dark, smooth cold brew, creating a subtle sweetness in the beverage.
- Oleato™ Iced Shaken Espresso : This coffee-forward beverage offers layers of flavor sweetened with notes of hazelnuts, rich espresso and creamy oatmilk infused with Partanna extra virgin olive oil.
In select markets, customers will also be able to add a press – the equivalent to a spoonful – of Partanna extra virgin olive oil as a customization to select beverages. The press will then be infused (steamed, shaken, or blended) as a customization into select drinks such as espresso beverages and tea lattes. Golden Foam will also be available as a customization, which can be added as a delicious topping on both hot and cold beverages.
Designed to pair perfectly with the exquisite Starbucks Reserve coffee, the Starbucks Reserve Roastery Milan today debuted five Starbucks Reserve Oleato beverages:
- Oleato™ Caffè Latte : Starbucks Reserve Espresso and creamy oatmilk infused with Partanna extra virgin olive oil create a velvety, luscious latte.
- Oleato™ Iced Cortado : Starbucks Reserve Espresso, demerara syrup, and a dash of orange bitters and oatmilk is infused with Partanna extra virgin olive oil. It is then served over ice and finished with an orange peel.
- Oleato™ Golden Foam™ Cold Brew : Starbucks Reserve Cold Brew is lightly sweetened with demerara syrup and finished with Partanna extra virgin olive oil infused cold foam, creating an inviting aroma and subtle sweetness.
- Oleato™ Deconstructed : An ode to the Italian tradition of combining olive oil with a squeeze of lemon. This beverage pairs Starbucks Reserve Espresso and Partanna extra virgin olive oil infused with a luxurious passionfruit cold foam.
- Oleato™ Golden Foam™ Espresso Martini : Starbucks Reserve Espresso, vodka and vanilla bean syrup topped with golden foam – a fusion of fior di latte (sweet cream) and Partanna extra virgin olive oil.
“When creating the beverages, we were inspired by the rich history and origin stories of coffee and olive oil – two of nature’s most transcendent ingredients,” said Amy Dilger, principal beverage developer for Starbucks. “Infusing Starbucks coffee with olive oil yielded a velvety smooth, rich texture, with the buttery, round flavors imparted by the olive oil perfectly pairing with the soft, chocolatey notes of the coffee.”
“One thing that’s special about Partanna’s olives is their uniquely nutty, slightly sweet flavors – think of that rich smoothness of a buttery caramel, it’s a natural complement to our coffee,” said Dilger. “Whether you enjoy Oleato hot or cold, you get this really luxurious, textural experience.”
Read more about the inspiration and creation of these beverages here.
Raising the Bar on Coffee Innovation
Italy’s romance with coffee, food and connection has served as an inspiration for the Starbucks Experience since the company’s earliest days, influencing its coffee, food, and store designs, as well as its reverence for artistry.
“The art of coffee craft, curation and creation remains core to Starbucks. Our aspiration to continue to be the world's leader in premium coffee – in both the art and the science – is as strong today as it was more than 50 years ago when Starbucks first opened its doors,” said Schultz. “Embracing our heritage, we remain dedicated to exceeding our customers’ expectations by bringing innovative experiences to savor.”
From the first Starbucks Caffè Latte served in 1984, to Pumpkin Spice Latte, Nitro Cold Brew, and the more recent Iced Shaken Espresso beverages, Starbucks continues to bring its customers innovative beverages at scale.
About Starbucks
Since 1971, Starbucks Coffee Company has been committed to ethically sourcing and roasting high-quality arabica coffee. Today, with nearly 36,000 stores worldwide, the company is the premier roaster and retailer of specialty coffee in the world. Through our unwavering commitment to excellence and our guiding principles, we bring the unique Starbucks Experience to life for every customer through every cup. To share in the experience, please visit us in our stores or online at stories.starbucks.com or starbucks.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230221005753/en/
Contact information
Email: press@starbucks.com
Hotline: 206-318-7100
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 01:00:00 EET | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemia (CLL), highlighting the foundational potential of this medicine. “The data we’re presenting at ASH 2025 are redefining what physicians can expect from sonrotoclax as a next-generation BCL2 inhibitor,” said Amit Agarwal, M.D., Ph.D., Chief Medical
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 18:00:00 EET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 14:00:00 EET | Press release
Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships Powering the Summit CoMotion GLOBAL 2025 is hosted by the Saudi Conventions & Exhibitions General Authority (SCEGA), supported by key Saudi
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 16:30:00 EET | Press release
Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 16:30:00 EET | Press release
Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. These findings further reinforce rusfertide’s efficacy and safety and demonstrate durability of response, with 61.9% of patients continuously treated with rusfertide maintaining absence of phlebotomy eligibility from baseline to Week 52. “The 52-week data demonstrated the sustained efficacy of rusfertide, reducing the need for patients to receive phlebotomy while maintaining hematocrit control,” said Dr. Andrew T. Kuykendall, M.D., VERIFY Lead Investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “The 32-week VERIFY primary results were already promising, and this deeper understanding of the durability of r
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
